The M50I polymorphic substitution in HIV-1 subtype B integrase does not restore viral fitness costs associated with the primary resistance mutation R263K
First-generation integrase strand-transfer inhibitors (INSTIs), such as raltegravir (RAL) and elvitegravir (EVG), have been clinically proven to be effective ARVs for the treatment of HIV-positive patients. However, their relatively low genetic barrier for resistance makes them susceptible to the em...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en |
| Published: |
McGill University
2014
|
| Subjects: | |
| Online Access: | http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=123258 |